Clinigen Group’s (CLIN) Buy Rating Reaffirmed at N+1 Singer
Clinigen Group (LON:CLIN)‘s stock had its “buy” rating reaffirmed by equities research analysts at N+1 Singer in a research note issued to investors on Wednesday. They presently have a GBX 1,225 ($16.61) price objective on the stock. N+1 Singer’s target price points to a potential upside of 22.87% from the stock’s current price.
Other equities analysts have also issued reports about the stock. Numis Securities reiterated an “add” rating and issued a GBX 1,208 ($16.38) price target on shares of Clinigen Group in a research note on Wednesday. Peel Hunt reiterated a “buy” rating and issued a GBX 1,350 ($18.31) price target on shares of Clinigen Group in a research note on Wednesday. Royal Bank of Canada reiterated an “outperform” rating and issued a GBX 1,360 ($18.44) price target on shares of Clinigen Group in a research note on Tuesday, November 7th. Finally, Berenberg Bank began coverage on shares of Clinigen Group in a research note on Wednesday, November 1st. They issued a “hold” rating and a GBX 1,200 ($16.27) price target on the stock. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Clinigen Group presently has a consensus rating of “Buy” and a consensus target price of GBX 1,218.83 ($16.53).
Clinigen Group (CLIN) opened at GBX 997 ($13.52) on Wednesday. The company has a market cap of $1,220.00 and a P/E ratio of 33,233.33. Clinigen Group has a one year low of GBX 751.50 ($10.19) and a one year high of GBX 1,187 ($16.10).
Clinigen Group Company Profile
Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.